Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors

Journal of Nuclear Medicine

Volumn 41, Issue 2, 2000, Pages 355-362

  Hornick, Jason L ^a   Sharifi, Jahangir ^a   Khawli, Leslie A ^a   Hu, Peisheng ^a   Bai, Wei Guo ^a   Alauddin, Mian M ^a   Mizokami, Myra M ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chimeric monoclonal antibody; FcRn; Immunoscintigraphy; Pharmacokinetics; Tumor targeting

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BODY DISTRIBUTION; CHIMERA; FEMALE; GENE AMPLIFICATION; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOLID TUMOR;

ADENOCARCINOMA; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; RADIOIMMUNODETECTION; TIME FACTORS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033953746     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg. 1991;214:118-124.
2. Moffat FL, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J Clin Oncol. 1996;14:2295-2305.
3. Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. Clin Nucl Med. 1997;22:615-620.
4. Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284-289.
5. 99mTc: the role of metabolism and kinetics. Cancer Res. 1995;55(suppl):5777S-5785S.
6. Podoloff DA, Patt YZ, Curley SA, Kim EE, Bhadkamkar VA, Smith RE. Imaging of colorectal carcinoma with technetium-99m radiolabeled Fab′ fragments. Semin Nucl Med. 1993;23:89-98.
7. 2 fragments in ovarian carcinoma patients. Cancer Res. 1993;53:5413-5418.
8. Behr TM, Becker WS, Bair H-J, et al. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med. 1995;36:430-441.
9. Ghetie V, Ward ES. FcRn: the MHC class 1-related receptor that is more than an IgG transporter. Immunol Today. 1997;18:592-598.
10. Kim J-K, Tsen M-F, Ghetie V, Ward ES. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol. 1994;24:542-548.
11. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol. 1997;158:2211-2217.
12. Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotechnol. 1997;15:637-640.
13. Hornick JL, Sharifi J, Khawli LA, et al. A chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiophar. 1998;13:255-268.
14. Pulvertaft RJV. Cytology of Burkitt's tumour (African lymphoma). Lancet. 1964;1:238-240.
15. Ohsugi Y, Gershwin ME, Owens RB, Nelson-Rees WA. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice. J Natl Cancer Inst. 1980;65:715-718.
16. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro. 1976;12:180-191.
17. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417-1423.
18. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809-1818.
19. Hu P, Glasky MS, Yun A, et al. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum Antibodies Hybridomas. 1995;6:57-67.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
21. Alauddin MM, Khawli LA, Epstein AL. An improved method of direct labeling monoclonal antibodies with technetium-99m. Nucl Med Biol. 1992;19:445-454.
22. Frankel ME, Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay: an analysis of the interaction between hybridoma proteins and influenza virus. Mol Immunol. 1979;16:101-106.
23. Epstein AL, Marder RJ, Winter JN, Fox RI. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J Immunol. 1984;133:1028-1036.
24. Zuckier LS, Georgescu L, Chang CJ, Scharff MD, Morrison SL. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer. 1994;73:794-799.
25. Hornick JL, Khawli LA, Hu P, Lynch M, Anderson PM, Epstein AL. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor largeting properties. Blood. 1997;89:4437-4447.
26. John E, Thakur ML, Wilder S, Alauddin MM, Epstein AL. Technetium-99m-labeled monoclonal antibodies: influence of technetium-99m binding sites. J Nucl Med. 1994;35:876-881.
27. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-Å resolution. Biochemistry. 1981;20:2361-2370.
28. H2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA. 1990;87:5702-5705.
29. H2 domain-deleted recombinant immunoglobulin. Int J Cancer. 1993;53:97-103.
30. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL. Pretreatment with a monoclonal antibody/interleukin 2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res. 1999;5:51-60.